HOME
SEARCH
RSS FEED
SUBSCRIBE
Identification and Use of Heterocyclic Alcohol Compounds for the Treatment of SULT1A1-expressing Cancers
Case ID:
TAB-3558
Web Published:
12/6/2022
Description:
This technology includes the identification and use of heterocyclic alcohol compounds, including RITA and N-BIC, for the treatment of SULT1A1-expression cancers. A high-throughput screen (qHTS) was performed using >1,000 caner cell lines identified a compound called YC-1 (also called Lificiguat) that is effective across cancer cell types that express the phase 2 detoxifying enzyme SULT1A1.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech/Identification_and_Use_of_Heterocycl ic_Alcohol_Compounds_for_the_Treatment_of_SULT1A1-expressing_Cancers
Category(s):
Research Materials
Therapeutics
Diagnostics
Oncology
Bookmark this page
Download as PDF
For Information, Contact:
Ami Gadhia
Technolgy and Patent Specialist
NIH Technology Transfer
301-827-7159
ami.gadhia@nih.gov
Inventors:
Min Shen
Ke Kong
Toble Lee
Samarjit Patnaik
Olivia Lee
Jonathan Shrimp
Mindy Davis
Juan Marugan
Wei Zhao
Matthew Hall
Keywords:
Agents
Alcohol
anti-cancer
Class
compounds
HETEROCYCLIC
SULT1A1-dependent
VCXXXX
WKXXXX
XCXXXX
XEXXXX
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum